glioma
Conditions
Interventions
IDH widetype glioma:no
Control samples include IDH mutant glioma and other nervous system tumors:no
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Pathological diagnosis as an IDH wildtype glioma patient 2) Age between 18-60 years old 3) Given standardized temozolomide treatment after surgery 4) The follow -up time is more than 6 months
Exclusion criteria
Exclusion criteria: 1) Patients die due to stroke, myocardial infarction, accident or other clinical diseases, and have any other diseases that have malignant tumors or can interfere with the results of the test. 2) Take other chemotherapy drugs other than omolizer 3) Inadequate clinical data, lack of follow -up data 4) Researchers believe that there are other factors that are not suitable for selection. Those who meet the above conditions shall not be selected
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PTRF;immune microenviroment analysis(CD68,MHCI,CD86,MHC ?,CD4,CD8 and so on); | — |
Secondary
| Measure | Time frame |
|---|---|
| DNA injury repair indicator;CD34; | — |
Countries
China
Contacts
Public ContactKang Chunsheng
Outcome results
None listed